(Q33603545)

English

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

28 July 2017

author name string

Akira Kubota

1

1 reference

Europe PubMed Central

28 July 2017

Ikuro Matsuba

2

1 reference

Europe PubMed Central

28 July 2017

Tatsuhiko Saito

3

1 reference

Europe PubMed Central

28 July 2017

Koichiro Nabe

4

1 reference

Europe PubMed Central

28 July 2017

Yutaka Seino

5

1 reference

Europe PubMed Central

28 July 2017

publication date

1 October 2011

1 reference

Europe PubMed Central

28 July 2017

Journal of Diabetes Investigation

1 reference

Europe PubMed Central

28 July 2017

2

1 reference

Europe PubMed Central

28 July 2017

5

1 reference

Europe PubMed Central

28 July 2017

377-380

1 reference

Europe PubMed Central

28 July 2017

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

GIP and GLP-1, the two incretin hormones: Similarities and differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Gut peptides and type 2 diabetes mellitus treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4019306

21 June 2018

SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Secretory unit of islet in transplantation (SUIT) and engrafted islet rate (EIR) indexes are useful for evaluating single islet transplantation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Impact of sitagliptin on markers of beta-cell function: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.2040-1124.2011.00109.X

21 January 2018

Identifiers

10.1111/J.2040-1124.2011.00109.X

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33603545&oldid=1947794906"